Eva Lentsch graduated with a M.D. from the University of Halle-Wittenberg in Germany. Because of Eva’s passionate interest in pancreatic cancer research her Ph.D., which she obtained from the University of Erlangen-Nürnberg in Germany under the supervision of Prof. Dr. Robert Grützmann focused on CRISPR/Cas mediated knockout in pancreatic cancer cell lines. Afterward, she studied immune checkpoint-associated genes in pancreatic cancer with a CRISPR/Cas screening. The Mildred-Scheel postdoctoral scholarship enables Eva the opportunity to work at the Tuveson Lab as a Postdoctoral Fellow. Her current research endeavors are focused on a CRISPR/Cas-mediated targeting of tumor microenvironment-associated genes in pancreatic cancer. This could unravel novel cell signaling pathways and lead to a new approach in pancreatic cancer therapy.